England could lose 16,000 GPs
England could lose 16,000 GPs.
FDA warns consumers about fraudulent Ebola treatment products
FDA warns consumers about fraudulent Ebola treatment products via FDA warns consumers about fraudulent Ebola treatment products. The U.S. Food and Drug Administration is advising consumers to be aware of products sold online claiming to prevent or treat the Ebola virus. Since the outbreak of the Ebola virus in West Africa, the FDA has seen […]
Coffee may help effects of obesity
Chemical in coffee may help prevent obesity-related disease Friday, 14 November 2014 Researchers at the University of Georgia have discovered that a chemical compound commonly found in coffee may help prevent some of the damaging effects of obesity. In a paper published recently in Pharmaceutical Research, scientists found that chlorogenic acid, or CGA, significantly reduced […]
FDA Approves Conversion of Soliris® (eculizumab) Accelerated Approval in aHUS to Regular Approval for the Treatment of Patients with aHUS
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque auctor aliquam lectus eget venenatis. Nam fermentum est quam, sit amet porttitor quam blandit nec. Morbi condimentum felis felis, in auctor sapien commodo ac. Donec eget felis arcu. Maecenas sit amet sapien vel eros commodo dictum. Aenean arcu orci, placerat ac consequat eget, facilisis et arcu. […]
European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia
European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with HypophosphatasiaEuropean Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with HypophosphatasiaEuropean Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with HypophosphatasiaEuropean Medicines Agency Accepts Marketing Authorization Application […]
European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)
European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)European Commission Grants Orphan […]